Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses
- 1 August 2016
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy Methods
- Vol. 27 (4) , 143-149
Abstract
We have described the development of capsid-modified next generation AAV vectors for both AAV2 and AAV3 serotypes, in which specific surface-exposed tyrosine (Y), serine (S), threonine (T), and lysine (K) residues on viral capsids were modified to achieve high-efficiency transduction at lower doses. We have also described the development of genome-modified AAV vectors, in which the transcriptionally-inactive, single-stranded AAV genome was modified to achieve improved transgene expression. Here, we describe that combination of capsid- and genome-modifications leads to the generation of optimized AAV serotype vectors, which transduce cells and tissues more efficiently, both in vitro and in vivo, at ~20-30-fold reduced doses. These studies have significant implications in the potential use of the optimized AAV serotype vectors in human gene therapy.Keywords
This publication has 32 references indexed in Scilit:
- Gene Therapy for Leber Hereditary Optic NeuropathyOphthalmology, 2016
- Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutionsJournal of Integrative Medicine, 2015
- Identification of small molecule inhibitors of Zcchc11 TUTase activityRNA Biology, 2015
- The overexpression and nuclear translocation of Trx-1 during hypoxia confers on HepG2 cells resistance to DDP, and GL-V9 reverses the resistance by suppressing the Trx-1/Ref-1 axisFree Radical Biology and Medicine, 2015
- Enhanced Transgene Expression from Recombinant Single-Stranded D-Sequence-Substituted Adeno-Associated Virus Vectors in Human Cell Lines In Vitro and in Murine Hepatocytes In VivoJournal of Virology, 2015
- Selective In Vivo Targeting of Human Liver Tumors by Optimized AAV3 Vectors in a Murine Xenograft ModelHuman Gene Therapy, 2014
- Efficient Production of Dual Recombinant Adeno-Associated Viral Vectors for Factor VIII DeliveryHuman Gene Therapy Methods, 2014
- Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trialThe Lancet, 2014
- Immune responses to AAV vectors: overcoming barriers to successful gene therapyBlood, 2013
- Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trialGene Therapy, 2012